Abstract: Devices, systems and methods for monitoring excitable cells, such as cardiomyocytes, on microelectrode arrays that couple the electro-stimulation of excitable cells to induce or regulate cardiomyocyte beating and the simultaneous measurement of impedance and extracellular recording to assess changes in cardiomyocyte beating, viability, morphology or electrophysical properties in response to a plurality of treatments.

Abstract: Aspects of the disclosed technology comprise generating firewall rules based on traffic, outputting the generated firewall rules to an output file, and using the output file to set firewall rules in a network. The firewall rules may be generated without a priori knowledge of the network; alternatively no firewall rules are required. Generated rules may be tuned for user preferences to adjust for the number of generated firewall rules, and their over or under inclusiveness to non-historic traffic data.

Abstract: A system for simulating network configurations includes data processing hardware and memory hardware in communication with the data processing hardware. The memory hardware stores instructions that when executed on the data processing hardware cause the data processing hardware to perform operations. The operations includes receiving one or more parameter changes for a production network model of a network. The operations also include generating a simulation network model including the one or more parameter changes. Another operation includes analyzing the simulated network flow within the simulation network model. The operations also include generating a report including an impact of the parameter changes on the network. The operations may also include receiving a production network log including a recorded workflow for the production network model and simulating the production workflow of the production network log within the simulation network model to generate a simulated network log.

Abstract: A suppression method of high-frequency resonance for VSC-HVDC (Voltage Source Converter-High Voltage Direct Current Transmission) system based on nonlinear filter in voltage feed-forward control. It includes that the nonlinear filter is used for the voltage feed-forward link in the current inner loop control. The specific method is to extract each sequence component of the AC (Alternating Current) voltage, calculate the average value of the sequence component at N sample points, compare the current average value with the output result of nonlinear filter in the previous period, and output the result of nonlinear filter in the current period. After corrected, the result is a fixed value varying according to gradient which acts on the voltage feed-forward link of the inner loop.

Abstract: In an example method, a mobile device obtains a database including a plurality of data records. Each data record includes an indication of a respective impact previously experienced by a user of the mobile device, and sensor data generated by one or more first sensors worn by the user during that impact. The mobile device obtains sensor data generated by one or more second sensors worn by the user over a period of time, and determines whether the user has fallen during the period of time based on the database and the additional sensor data. The mobile device generates one or more notifications based on the determination of whether the user has fallen during the period of time.

Abstract: In an example method, a mobile device receives motion data obtained by one or more sensors over a time period, where the one or more sensors are worn by a user, The mobile device determines, based on the motion data, an impact experienced by the user during the time of period, and determines one or more of characteristics of the user. The mobile device determines, based on the motion data and the one or more characteristics of the user, a likelihood that the user requires assistance subsequent to the impact, and generates one or more notifications based on likelihood.

Abstract: This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.

Abstract: A method for catalytic cracking of naphtha is provided. Naphtha is catalytically cracked under the action of a catalyst. The catalyst includes aluminosilicate, alkali metal oxide, alkaline earth metal oxide, TiO2, iron oxide, vanadium oxide and nickel oxide. On the other hand, a rapid separation component is arranged in a disengager of a catalytic cracking reaction device, so that a transport disengaging height is greatly reduced without changing a gas flow and a diameter of the disengager. In addition, the separation efficiency of oil gas and the catalyst is improved.

Abstract: This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.

Abstract: A surgical knife safety device having a handle, a blade connected to the handle, and a guard carried by the handle for sliding movement between a retracted position in which the blade is exposed for use, and an extended position for covering the sharp cutting edge of the blade. In the retracted position, an enlarged guard radius is provided at the distal end of the handle to allow improved handle control and blade orientation. The enlarged guard radius is positioned to allow the user to firmly grip a large distal handle portion which is preferably molded as a single piece with the blade holder, preventing unwanted blade or handle movement due to guard mechanism tolerances. A spring, such as leaf spring or a cantilever beam, and a pair of detents or slots are provided to fix the guard in the extended or retracted position and to provide resistance during movement between the two positions.

Abstract: The present disclosure relates to novel crystalline forms of GFT-505, processes for preparation and uses thereof. The crystalline form CS1, crystalline form CS2, crystalline form CS5 and crystalline form CS6 of GFT-505 provided by the present disclosure have high purity, good stability, low hygroscopicity, good solubility and good mechanical stability. The present disclosure provides a new and better choice for the preparation of drug products containing GFT-505 and is of great significance for drug development.

Abstract: The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.

Abstract: The processing load on a host processor is substantially reduced by offloading the transport layer security protocol, such as the TLS/SSL protocol, the transport layer protocol stack, such as the TCP/IP protocol stack, and the network control required to access a network, such as the Internet, onto an expansion device.

Abstract: The present disclosure relates to a crystalline form of compound I and processes for preparation thereof. The present disclosure also relates to a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing serotonin, norepinephrine and dopamine triple reuptake inhibitors drugs, and/or use of the crystalline form for preparing drugs treating nervous system disorders. The crystalline form of the present disclosure has one or more improved properties compared with prior art and has significant values for future drug optimization and development.

Abstract: The present disclosure relates to novel crystalline forms of compound (I) and processes for preparation and use thereof. Crystalline forms CS3, CS2, CS5 and CS8 of compound (I) of the present disclosure have advantages in at least one aspect of solubility, stability, melting point, hygroscopicity, particle size, bioavailability, processability, purification effect, flowability, adhesiveness, stability in drug product, in vitro and in vivo dissolution, etc., which provides new and better choices for preparation of drug product containing compound (I) and has significant values for future drug development.

Abstract: The present disclosure relates to novel crystalline forms of ozanimod and preparation method thereof. The provided crystalline forms of ozanimod comprise crystalline form CS9, crystalline form CS10 and crystalline form CS11, and can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, stability, hygroscopicity and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.

Abstract: The present disclosure relates to crystalline forms of Baricitinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical composition containing these crystalline forms and use of these crystalline forms for preparing JAK inhibitor drugs and preparing drugs treating rheumatoid arthritis. The crystalline forms of the present disclosure have one or more improved properties compared with crystalline forms of the prior art and have significant values for future drug optimization and development.

Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.

Abstract: The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.

Abstract: A surgical knife safety device having a handle, a blade connected to the handle, and a guard carried by the handle for sliding movement between a retracted position in which the blade is exposed for use, and an extended position for covering the sharp cutting edge of the blade. A spring, such as leaf spring or a cantilever beam, and a pair of detents or slots are provided to fix the guard in the extended or retracted position and to provide resistance during movement between the two positions.